Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study.
BACKGROUND
The aim of this study was to evaluate pp65 antigen-guided antiviral therapy in preventing human cytomegalovirus (HCMV) infection in solid organ transplant recipients.


METHODS
Ten kidney and two liver transplant recipients with asymptomatic HCMV infection were randomized either for i.v. ganciclovir or placebo treatment in a prospective, double-blind study. All patients were positive by HCMV pp65 antigen test at levels >5 positive cells/2 x 10(5) investigated cells.


RESULTS
No cases of HCMV end-organ disease occurred. In contrast to patients on placebo (5/7), none of the patients on ganciclovir (0/5) developed HCMV-associated symptoms (P=0.01). However, because of the small number of patients, all three high-risk patients (donor seropositive, recipient seronegative) were randomized to placebo and all three developed symptoms.


CONCLUSIONS
Preemptive antiviral therapy guided by the pp65 antigen test seems to have a beneficial effect on preventing HCMV-associated symptoms in kidney and liver transplant recipients.
Koetz
A C
AC
Section of Transplantation Surgery, University Hospital Freiburg, Germany.
Delbrück
R
R
Furtwängler
A
A
Hufert
F T
FT
Neumann-Haefelin
D
D
Kirste
G
G
Meyer-König
U
U
D000998:Antiviral Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D004311:Double-Blind Method; D016503:Drug Delivery Systems; D015774:Ganciclovir / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D016030:Kidney Transplantation; D016031:Liver Transplantation; D010750:Phosphoproteins / Q000627:therapeutic use*; D011446:Prospective Studies; D014763:Viral Matrix Proteins / Q000627:therapeutic use*
D000998:Antiviral Agents; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa; D015774:Ganciclovir